The 5-year survival for all cancers is 79.1%, as compared to 76.1% before 2001.
The two main messages from the paper are :
- No improvement in paediatric malignancies with the poorest prognosis (brain, neuroblastoma, sarcoma), while prognosis of AML remains poor;
- Significant disparity in survival across Europe with 10 to 20 % less in Eastern European countries.
These data along with cancer survival in adults (published in the same issue of The Lancet Oncology) have been discussed in the European Parliament during a meeting organized by ‘MEPs against Cancer’ and MEP A. Peterle. The SIOPE Office made a press release covering both these important research results and the event.
This is against this background that the ENCCA project (in which SIOPE is a key partner) is currently preparing a ‘long-term sustainability’ project and a strategic plan, in order to increase both cure and quality of cure in children and adolescents with cancer.